drugset

drugset / Trial / NCT01935518

A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01935518 ↗

Phase 2 Unknown 10 enrolled Peking University Third Hospital

NaSingle-groupOpen-labelTreatment

Summary

This study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (ALS).

Timeline

Start: 2013-09
Primary completion: 2015-03
Completion: 2015-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fasudil	Small molecule	30 mg	Intravenous

Indications